EGFR and non-small cell lung carcinoma: In addition, HARMONi‐A trial also showed that ivonescimab, a PD‐1/VEGF bispecific antibody, in combination with chemotherapy significantly improved PFS compared with chemotherapy alone in patients with EGFR‐mutated NSCLC who had progressed on EGFR‐TKI treatment.40